Michael Byrne

3.8k total citations
81 papers, 1.4k citations indexed

About

Michael Byrne is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Michael Byrne has authored 81 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Hematology, 26 papers in Molecular Biology and 19 papers in Oncology. Recurrent topics in Michael Byrne's work include Acute Myeloid Leukemia Research (27 papers), Hematopoietic Stem Cell Transplantation (21 papers) and Chronic Myeloid Leukemia Treatments (13 papers). Michael Byrne is often cited by papers focused on Acute Myeloid Leukemia Research (27 papers), Hematopoietic Stem Cell Transplantation (21 papers) and Chronic Myeloid Leukemia Treatments (13 papers). Michael Byrne collaborates with scholars based in United States, France and India. Michael Byrne's co-authors include Bipin N. Savani, Richard D. Kim, Pavan Kumar, Mamoru Yanagimachi, Crystal MacKenzie, Ken Aoshima, Zoltán Dezső, Judy Oestreicher, Sergei Agoulnik and Yoshiya Oda and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Michael Byrne

75 papers receiving 1.4k citations

Peers

Countries citing papers authored by Michael Byrne

Since Specialization

Citations

This map shows the geographic impact of Michael Byrne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Byrne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Byrne more than expected).

Fields of papers citing papers by Michael Byrne

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Byrne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Byrne. The network helps show where Michael Byrne may publish in the future.

Co-authorship network of co-authors of Michael Byrne

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Byrne. A scholar is included among the top collaborators of Michael Byrne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Byrne. Michael Byrne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	ZUMA-8: a phase 1 study of brexucabtagene autoleucel in patients with relapsed/refractory chronic lymphocytic leukemia 2025 ·PubMed ·Matthew S. Davids, Saad S. Kenderian, Ian W. Flinn, Brian T. Hill, Michael B. Maris, Paolo Ghia, Michael Byrne, Nancy L. Bartlett, John M. Pagel, Yan Zheng, (unknown), Wangshu Zhang, (unknown), Javier Pinilla‐Ibarz	2
2	Key Challenges in CAR T-Cell Therapy Access in Community Oncology 2025 ·JAMA Oncology ·Michael Byrne, (unknown), Samyukta Mullangi	2
3	Prognostic Value of Cutaneous Disease Severity Estimates on Survival Outcomes in Patients With Chronic Graft-vs-Host Disease 2023 ·JAMA Dermatology ·Emily Baumrin, (unknown), Michael Byrne, Paul J. Martin, Mary E.D. Flowers, Lynn Onstad, Najla El Jurdi, Heidi Chen, Alicia Beeghly‐Fadiel, Stephanie J. Lee, Eric R. Tkaczyk	7
4	Prolonged Post-Transplant Ruxolitinib Therapy is Associated with Protection from Severe Gvhd after Allogeneic HCT 2022 ·Transplantation and Cellular Therapy ·Zachariah DeFilipp, Haesook T. Kim, Laura Knight, (unknown), Michael Byrne, Mark A. Schroeder, Roni Tamari, Sarah Wall, Sumithira Vasu, Sameem Abedin, Areej El‐Jawahri, Steven L. McAfee, Yi‐Bin Chen, Gabriela Hobbs	2
5	Phase II Trial of Eprenetapopt (APR-246) in Combination with Azacitidine (AZA) As Maintenance Therapy for TP53 mutated Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) Following Allogeneic Hematopoietic Cell Transplantation (HCT) 2022 ·Transplantation and Cellular Therapy ·Asmita Mishra, Roni Tamari, Amy E. DeZern, Michael Byrne, Mahasweta Gooptu, Yi‐Bin Chen, H. Joachim Deeg, (unknown), Anders Wennborg, Denice Hickman, Eyal C. Attar, Hugo F. Fernández	1
6	Reduction in the Prevalence of Thrombotic Events in Sickle Cell Disease after Allogeneic Hematopoietic Transplantation 2022 ·Transplantation and Cellular Therapy ·(unknown), (unknown), Heidi Chen, Deva Sharma, Michael Byrne, Jennifer Green, Salyka Sengsayadeth, Bhagirathbhai Dholaria, Bipin N. Savani, Wichai Chinratanalab, Reena Jayani, Katie S. Gatwood, Brian G. Engelhardt, Carrie L. Kitko, James A. Connelly, Adetola A. Kassim	3
7	Reduced Insulin Sensitivity in Patients with Myeloid Malignancies and Clonal Hematopoiesis Mutations 2020 ·Blood ·Uttam K. Rao, Heidi Chen, Katie S. Gatwood, Michael Byrne, Salyka Sengsayadeth, Stacey Goodman, Bhagirathbhai Dholaria, Adetola A. Kassim, Bipin N. Savani, Wichai Chinratanalab, Kathryn A. Culos, Michael R. Savona, Brian G. Engelhardt	1
8	434 Association of skin response in erythema and sclerosis with survival in chronic graft-versus-host disease 2020 ·Journal of Investigative Dermatology ·(unknown), Michael Byrne, Paul J. Martin, (unknown), (unknown), Madan Jagasia, Eric R. Tkaczyk	2
9	Indications for Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome 2020 ·Current Hematologic Malignancy Reports ·(unknown), Michael Byrne	3
10	Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase Inhibition 2019 ·Blood ·Tamara K. Moyo, Justin M. Watts, Barry Skikne, Jason H. Mendler, Virginia M. Klimek, Sheau‐Chiann Chen, Run Fan, Ingrid Anderson, Andrew Sochacki, Stephen A. Strickland, Michael Byrne, Terrence Bradley, Gregory D. Ayers, Sanjay Mohan, Michael R. Savona	10
11	Salvage Therapy after Allogeneic Hematopoietic Cell Transplantation: Targeted and Low-Intensity Treatment Options in Myelodysplastic Syndrome and Acute Myeloid Leukemia 2019 ·SHILAP Revista de lepidopterología ·(unknown), Michael Byrne	10
12	Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy 2019 ·Biology of Blood and Marrow Transplantation ·Michael Byrne, Olalekan O. Oluwole, Bipin N. Savani, Navneet S. Majhail, Brian T. Hill, (unknown)	62
13	Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma 2018 ·Bone Marrow Transplantation ·(unknown), Sharon Phillips, Michael Byrne, Wichai Chinratanalab, Brian G. Engelhardt, Stacey Goodman, (unknown), Madan Jagasia, Adetola A. Kassim, (unknown), Bipin N. Savani, Salyka Sengsayadeth, Robert F. Cornell	13
14	Defining Incidence and Risk Factors for Catheter-Associated Bloodstream Infections in an Outpatient Adult Hematopoietic Cell Transplantation Program 2018 ·Biology of Blood and Marrow Transplantation ·(unknown), Kathryn A. Culos, Katie S. Gatwood, (unknown), Heidi Chen, Bipin N. Savani, Michael Byrne, Adetola A. Kassim, Brian G. Engelhardt, Madan Jagasia, Gowri Satyanarayana	10
15	Preliminary Results from an Ongoing Phase 1/2 Study of INCB053914, a Pan-Proviral Integration Sites for Moloney Virus (PIM) Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies 2017 ·Blood ·Michael Byrne, William B. Donnellan, Manish R. Patel, Amer M. Zeidan, Mohamad Cherry, Maria R. Baer, Amir T. Fathi, Jason Kaplan, Feng Zhou, (unknown), April Barbour, Michael R. Savona	8
16	Metabolic Complications Precede Alloreactivity and Are Characterized by Changes in Suppression of Tumorigenicity 2 Signaling 2016 ·Biology of Blood and Marrow Transplantation ·Romany Johnpulle, Sophie Paczesny, Dae Kwang Jung, Étienne Daguindau, Madan Jagasia, Bipin N. Savani, Wichai Chinratanalab, Robert F. Cornell, Stacey Goodman, John P. Greer, Adetola A. Kassim, Salyka Sengsayadeth, Michael Byrne, Brian G. Engelhardt	13
17	Influence of HIV on Lower Genital Tract Neoplasia1 2015 ·Antibiotics and chemotherapy/Antibiotica et chemotherapia ·Justin Smith, Marc Botcherby, (unknown), Michael Byrne, P. Mason, S M Forster	0
18	Progressive Genomic Instability in the Nup98-HoxD13 Model of MDS Correlates with Loss of the PIG-A Gene Product 2014 ·Neoplasia ·Michael Byrne, Richard L. Bennett, Xiaodong Cheng, W. Stratford May	10
19	Safety and Feasibility of Using Sorafenib in Recurrent Hepatocellular Carcinoma after Orthotopic Liver Transplantation 2010 ·Oncology ·Richard D. Kim, Galal El‐Gazzaz, Ann Tan, Paul Elson, Michael Byrne, (unknown), Federico Aucejo	39
20	Prediction of amputation wound healing with skin perfusion pressure 1995 ·Journal of Vascular Surgery ·(unknown), Kevin V. James, John J. Castronuovo, Michael Byrne, (unknown), Joanne M. Lohr	72

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact